Personalizing KRAS-Mutant Allele-Specific Therapies

Chiara Falcomatà Günter Schneider Dieter Saur 

 2020 Jan;10(1):23-25.

DOI: 10.1158/2159-8290.CD-19-1261


KRAS G12R mutations occur almost exclusively in pancreatic ductal adenocarcinoma. The results of a study that reveals specific differences in KRAS downstream signaling and metabolic rewiring of pancreatic cancer cells harboring KRAS G12R mutations promise to improve our possibilities to better stratify patients for individualized therapies.See related article by Hobbs et al., p. 104.